Jyothi Parvathareddy

发表

Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19

Tudor I. Oprea, Steven B. Bradfute, T. Oprea, 2020, ACS pharmacology & translational science.

NaxD is a deacetylase required for lipid A modification and Francisella pathogenesis

Mark A. Miller, F. Song, C. Raetz, 2012, Molecular microbiology.

Mitochondrial Dynamics and Oxidative Stress Exposure to environmentally persistent free radicals during gestation lowers energy expenditure and impairs skeletal muscle mitochondrial function in adult mice

D. Bridges, Jyothi Parvathareddy, Joan C. Han, 2016 .

Genetic control of weight loss during pneumonic Burkholderia pseudomallei infection.

Mark A. Miller, Robert W. Williams, Y. Cui, 2014, Pathogens and disease.

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2

Russell B. Davidson, D. Sterner, S. Pokhrel, 2022, Nature Communications.

Emergence and Magnitude of ML336 Resistance in Venezuelan Equine Encephalitis Virus Depend on the Microenvironment

Jennifer E. Golden, C. Jonsson, Jyothi Parvathareddy, 2020, Journal of Virology.

Cardiopulmonary Injury in the Syrian Hamster Model of COVID-19

Shannon L. Taylor, Ying Kong, Jyothi Parvathareddy, 2022, Viruses.

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity

J. Louis, P. Bonnesen, K. Weiss, 2022, Research square.

A galU mutant of francisella tularensis is attenuated for virulence in a murine pulmonary model of tularemia

Mark A. Miller, F. Re, J. Bina, 2011, BMC Microbiology.

Visualization of Murine Intranasal Dosing Efficiency Using Luminescent Francisella tularensis: Effect of Instillation Volume and Form of Anesthesia

Mark A. Miller, Thomas P. Fabrizio, J. Bina, 2012, PloS one.

Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants

Amanda P. Smith, I. Nookaew, C. Jonsson, 2023, Viruses.

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

J. Louis, P. Bonnesen, K. Weiss, 2022, Nature Communications.

Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study

Duane D. Miller, B. Meibohm, C. Jonsson, 2021, J. Chem. Inf. Model..

AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2

M. Head, G. Phillips, Qiu Zhang, 2023, J. Chem. Inf. Model..

Rapid Sequencing of Multiple RNA Viruses in Their Native Form

I. Nookaew, D. Ussery, C. Jonsson, 2018, bioRxiv.

Efficacy of a brain-penetrant antiviral in lethal Venezuelan and eastern equine encephalitis mouse models

Jennifer E. Golden, B. Meibohm, C. Jonsson, 2023, Science Translational Medicine.

Upper Respiratory Infection Drives Clinical Signs and Inflammatory Responses Following Heterologous Challenge of SARS-CoV-2 Variants of Concern in K18 Mice

R. Webby, Ying Kong, Jyothi Parvathareddy, 2023, Viruses.

Exposure to environmentally persistent free radicals during gestation lowers energy expenditure and impairs skeletal muscle mitochondrial function in adult mice

Jyothi Parvathareddy, S. Cormier, Jordy Saravia, 2016, American journal of physiology. Endocrinology and metabolism.

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2

Jerry M. Parks, Russell B. Davidson, D. Sterner, 2023, Nature Communications.